DENVER – NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF) is pleased to announce that its flagship subsidiary, NanoSphere Health Sciences, LLC, has been granted Patent No. 9,925.149—which covers the core technology behind the production of the NanoSphere Delivery System™—by the United States Patent and Trademark Office.
Theresearch-proven NanoSphere Delivery System™, protected by this patent, is one of the most important advancements for the non-invasive delivery of biological agents in over 25 years. The patent broadly encompasses the formation and manufacturing of the NanoSphere Delivery System for the delivery of cannabinoids, pharmaceuticals, nutraceuticals, cosmeceuticals and other biological agents.
NanoSphere’s groundbreaking NanoSphere Delivery System™ nanoencapsulates a broad range of bioactive compounds in a protective membrane, transporting them rapidly and effectively to the bloodstream and cells for greater efficacy. This delivery platform is a breakthrough in pharmaceutical, cannabinoid, nutraceutical and cosmeceutical supplement delivery. It makes the nanoencapsulated agents safer and more bioavailable, reducing adverse effects by delivering precise doses of smart nanoparticles to target sites.
“The granting of the patent for the NanoSphere Delivery System™ secures our position as a leader in advanced nanoparticle delivery,” said Robert Sutton, CEO of NanoSphere Health Sciences.
“Major industries have the potential to be reshaped and reimagined by our next-generation technology.”
“NanoSphere’s patent claims and protects our core technology for the formation and manufacturing of lipid, structural nanoparticles, which is the NanoSphere Delivery System™,” said Dr. Richard Clark Kaufman, Chief Science Officer and inventor of the NanoSphere Delivery System™. “This patent extends to our 16 forms of lipid nanoparticle structures, which can be applied across healthcare sectors for vastly improved medical delivery.”
With the issuance of this patent, the NanoSphere will now have long-term market exclusivity over this delivery platform, with patent infringement prohibited.
The company intends to license the patented NanoSphere Delivery System™ and proprietary manufacturing process to selected companies in its target industries to maximize commercialization.
This patent allows NanoSphere to bring to the world the NanoSphere Delivery System™ through multiple product lines and platforms, such as the company’s cannabis brand Evolve Formulas’ transdermal, intranasal and intraoral applications and beyond.
